# AstraZeneca Plc’s Enhertu approved in the US for HER2+ solid tumours

- Link: https://www.directorstalkinterviews.com/astrazenecas-enhertu-approved-in-the-us-for-her2-solid-tumours/4121150610
- Published: 2024-04-08T07:32:40+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and Daiichi Sankyo’s _Enhertu_ (trastuzumab deruxtecan) has been approved in the
US for the treatment of adult patients with unresectable or metastatic HER2-positive(
IHC 3+) solid tumours who have received prior systemic treatment and have no satisfactory
alternative treatment options.

This indication is approved under accelerated approval based on objective response
rate (ORR) and duration of response (DoR). Continued approval for this indication
may be contingent upon verification and description of clinical benefit in a confirmatory
trial.

_Enhertu_ is a specifically engineered HER2-directed antibody drug conjugate (ADC)
discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca
and Daiichi Sankyo.

The first tumour-agnostic approval of a HER2-directed therapy and ADC by the Food
and Drug Administration (FDA) was based on results from the subgroup of patients
with HER2-positive IHC 3+ tumours in each of the DESTINY-PanTumor02, DESTINY-Lung01
and DESTINY-CRC02 Phase II trials.

Funda Meric-Bernstam, MD, Chair of Investigational Cancer Therapeutics at The University
of Texas MD Anderson Cancer Center, US, said: “Until the approval of trastuzumab
deruxtecan, patients with metastatic HER2-positive solid tumours have had limited
treatment options. Based on the clinically meaningful response rates seen across
clinical trials, this tumour-agnostic approval means that patients may now be treated
with a HER2-directed medicine.”

Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca,
said: “As the first antibody drug conjugate to be granted a tumour-agnostic indication,
_Enhertu_ is truly delivering on its potential across metastatic HER2-targetable
tumours. This approval also elevates the importance of testing for biomarkers, including
HER2, across a broad range of tumours to ensure these patients with advanced cancer
who have few options know whether a targeted medicine might be right for them.”

Ken Keller, Global Head of Oncology Business, and President and CEO, Daiichi Sankyo,
Inc., said: “This fifth indication in the US is a significant milestone as eligible
patients with previously treated metastatic HER2-positive solid tumours may now 
be treated with _Enhertu_. The accelerated approval by the FDA for this tumour-agnostic
indication is based on the clinically meaningful efficacy seen with _Enhertu_ across
numerous types of metastatic cancers.”

In the DESTINY-PanTumor02 Phase II trial, patients with centrally or locally assessed
HER2-positive (IHC 3+) solid tumours including either biliary tract, bladder, cervical,
endometrial, ovarian, pancreatic or other tumours treated with _Enhertu_ showed 
a confirmed ORR of 51.4% (95% confidence interval [CI] 41.7-61.0) and a median DoR
range of 19.4 months (range 1.3-27.9+ [+ denotes ongoing responses at data cutoff]).
In DESTINY-Lung01, patients with centrally confirmed HER2-positive (IHC 3+) non-
small cell lung cancer (NSCLC) treated with _Enhertu_ showed a confirmed ORR of 
52.9% (95% CI 27.8-77.0) and median DoR range of 6.9 months (range 4.0-11.7+). A
confirmed ORR of 46.9% (95% CI 34.3-59.8) and median DoR range of 5.5 months (range
1.3+-9.7+) was seen in patients with centrally confirmed HER2-positive (IHC 3+) 
colorectal cancer in the DESTINY-CRC02 trial.

The safety of _Enhertu_ was evaluated in 347 patients with unresectable or metastatic
HER2-positive (IHC 3+) solid tumours in the DESTINY-Breast01, DESTINY-PanTumor02,
DESTINY-Lung01 and DESTINY-CRC02 trials. The safety profile observed across the 
trials was consistent with previous clinical trials of _Enhertu_ with no new safety
concerns identified.

Based on these results, _fam-trastuzumab deruxtecan-nxki_ (_Enhertu_) has been included
in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^(®)) as a 
treatment option for multiple metastatic tumours. See NCCN Guidelines^(®) for detailed
recommendations.^(1)

This approval was granted under the FDA’s Real-Time Oncology Review programme after
securing Priority Review and Breakthrough Therapy Designation for _Enhertu_ in the
US in this setting.

The US regulatory submission was reviewed under Project Orbis, which provides a 
framework for concurrent submission and review of oncology medicines among participating
international partners. As part of Project Orbis, _Enhertu_ is also under regulatory
review for the same indication by regulatory authorities in Australia, Brazil and
Singapore.

**Financial considerations**

Sales of _Enhertu_ in the US are recognised by Daiichi Sankyo. AstraZeneca reports
its share of gross profit margin from _Enhertu_ sales in the US as alliance revenue
in the Company’s financial statements.

Further details on the financial arrangements were set out in the March 2019 announcement
of the collaboration.

Share on:
